| 0 (0%) | 09-27 11:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.65  |
1-year : | 4.91 |
| Resists | First : | 3.98 |
Second : | 4.21 |
| Pivot price | 3.85 |
|||
| Supports | First : | 3.63 |
Second : | 3.02 |
| MAs | MA(5) : | 3.78 |
MA(20) : | 3.86 |
| MA(100) : | 4.16 |
MA(250) : | 5.49 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.2 |
D(3) : | 21.1 |
| RSI | RSI(14): 35 |
|||
| 52-week | High : | 9.19 | Low : | 3.61 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KZR ] has closed above bottom band by 6.2%. Bollinger Bands are 17.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.81 - 3.83 | 3.83 - 3.85 |
| Low: | 3.58 - 3.61 | 3.61 - 3.63 |
| Close: | 3.61 - 3.65 | 3.65 - 3.69 |
Wed, 17 Sep 2025
All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy - Nasdaq
Thu, 28 Aug 2025
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Business Wire
Thu, 17 Jul 2025
H.C. Wainwright Maintains Kezar Life Sciences(KZR.US) With Hold Rating - 富途牛牛
Tue, 13 May 2025
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
Thu, 08 May 2025
Kalamazoo renews Victorian focus on gold-antimony exploration - Mining.com.au
Wed, 13 Nov 2024
Kezar struck again with second FDA hold - Clinical Trials Arena
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 7 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 10.5 (%) |
| Held by Institutions | 63.9 (%) |
| Shares Short | 800 (K) |
| Shares Short P.Month | 589 (K) |
| EPS | -9.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.8 % |
| Return on Equity (ttm) | -58.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -7.39 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -0.38 |
| PEG Ratio | 0 |
| Price to Book value | 0.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|